New ASSET Center
Penn Engineering’s newly formed ASSET (AI-enabled Systems: Safety, Explainablity and Trustworthiness) Center is part of Penn Engineering’s Innovation in Data Engineering & Science (IDEAS) Initiative.
COVID Vaccines and Boosters Provoke Robust Immune Response
Several new research studies reported in the New York Times have demonstrated that multiple doses of a COVID vaccine elicit a durable response in most people that protects them from serious illness
Newly discovered ‘encrypted peptides’ with antibiotic properties
A new study reports three distinct proteins in human plasma that have naturally occurring antibiotic properties. Global public health officials are concerned about the r
Decade-long remission after CAR T cell therapy
Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.
ExynAI has been shortlisted as a finalist for a SXSW Innovation Award
For the 2022 category of Robotics and Hardware. The Exyn team will be going to Austin for the awards.
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Halting Progress and Happy Accidents: How mRNA vaccines were made
A New York Times feature on the history, research, challenges, and timeline to make the COVID-19 mRNA vaccines.
Moderna forms oncology collaboration with Carisma Therapeutics
Moderna will collaborate with Penn spinout Carisma Therapeutics to discover, develop and commercialize in-vivo engineered chimeric antigen receptor monocyte therapeutics for the treatment of cancer.
From foundational discoveries to profound impact
Without the mRNA technology foundation laid by Karikó and Weissman, the Pfizer/BioNTech and Moderna vaccines being deployed across the world would not exist.
Technology used in mRNA COVID vaccines offers hope for treatment of millions with heart disease, study suggests
Combining technologies that proved hugely success against cancer and in COVID-19 vaccines, researchers at Penn have shown they can effectively treat a leading cause of heart disease.